Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application
Authors' conclusion
In conclusion, DEX effectively mitigates renal IRI, as evidenced by robust in vitro, in vivo, and clinical studies. It significantly reduces kidney damage and improves surgical outcomes. However, its efficacy is less pronounced in kidney transplantation, suggesting that its renoprotective effects vary depending on the clinical context.
Study context
- Population
- Renal ischaemia-reperfusion injury (IRI) in cellular, animal and clinical studies across surgical and clinical settings
- Comparison
- Dexmedetomidine for renal ischaemia–reperfusion injury
Main finding
As reported in the abstract
- Dexmedetomidine (DEX) reduces oxidative stress, inflammation, apoptosis, ferroptosis, cellular senescence and renal fibrosis, and enhances mitochondrial function and autophagy
- DEX mitigates renal IRI, improves postoperative renal outcomes and lowers acute kidney injury (AKI) incidence in various surgical settings
- Efficacy less pronounced in kidney transplantation
Original publication
Dexmedetomidine mitigation of renal ischaemia–reperfusion injury: comprehensive insights from cellular mechanisms to clinical application. Br J Anaesth. Published 12 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →